Pasithea Therapeutics Acquires AlloMek Therapeutics

Pasithea Therapeutics Acquires Alpha-5 Integrin, LLC

June 22, 2022

Biotechnology

Pasithea Therapeutics Corp. acquired all outstanding equity interests in Alpha-5 Integrin, LLC, a preclinical biotechnology company developing a monoclonal antibody targeting α5 integrin for ALS and other neuroinflammatory disorders. The transaction was valued at $3.75 million and was paid primarily in Pasithea common stock (3,260,870 shares) plus warrants; an entity controlled by Paul B. Manning was Alpha-5's majority owner prior to the deal.

Sorrento Therapeutics Acquires ACEA Therapeutics

June 1, 2021

Biotechnology

Sorrento Therapeutics completed the acquisition of ACEA Therapeutics, making ACEA a wholly owned subsidiary and issuing Sorrento common stock plus contingent milestone and royalty payments. The deal adds multiple clinical- and preclinical-stage new chemical entities (including abivertinib) to Sorrento's oncology and immunotherapy pipeline and expands its development and manufacturing footprint in China and North America.

Biogen Acquires Alcyone Therapeutics

September 19, 2025

Medical Devices

Biogen has acquired Alcyone Therapeutics to obtain the ThecaFlex DRx intrathecal drug‑delivery system, integrating Alcyone employees into Biogen’s product delivery solutions team. Alcyone will receive $85 million upfront plus contingent milestone payments; Biogen will handle development, commercialization and manufacturing of ThecaFlex DRx while Alcyone’s remaining therapeutic assets are being divested into Neela Therapeutics.

Syros Pharmaceuticals Merges with TYME Technologies

September 16, 2022

Biotechnology

Syros Pharmaceuticals completed a merger with TYME Technologies, acquiring TYME's pipeline assets and approximately $60 million of net cash at closing. The transaction was accompanied by an oversubscribed $130 million PIPE financing to provide capital for Syros' late-stage hematology programs and early commercialization activities.

PureTech Acquires Remaining Interest in Alivio Therapeutics

June 16, 2021

Biotechnology

PureTech Health plc acquired the remaining 22% of shares in its Founded Entity, Alivio Therapeutics, integrating Alivio's anti-inflammatory therapeutic programs — including LYT-500 and LYT-503/IMB-150 — into PureTech's Wholly Owned Pipeline. The transaction consolidates PureTech's ownership of Alivio and is expected to fund and advance the programs through PureTech's immunology and related technology capabilities.

Sensei Biotherapeutics Acquires Faeth Therapeutics

February 18, 2026

Biotechnology

Sensei Biotherapeutics (Nasdaq: SNSE) has acquired clinical-stage Faeth Therapeutics in a stock-for-stock transaction that brings Faeth's lead oncology asset PIKTOR into Sensei's pipeline. Concurrently Sensei raised approximately $200 million in a private placement of Series B non-voting convertible preferred stock from a syndicate of institutional life-sciences investors to advance PIKTOR through Phase 2 topline data and initiate a Phase 1b breast cancer trial.